{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:54:59Z","timestamp":1790801699822,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.jcf.2023.01.005","type":"journal-article","created":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T15:28:53Z","timestamp":1673882933000},"page":"478-483","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Drug-drug interactions with CFTR modulator therapy in cystic fibrosis: Focus on Trikafta\u00ae\/Kaftrio\u00ae"],"prefix":"10.1016","volume":"22","author":[{"given":"Debanjali","family":"Purkayastha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyla","family":"Agtarap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3881-9746","authenticated-orcid":false,"given":"Kristy","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onella","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jannie","family":"Co","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smita","family":"Pakhale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0594-0360","authenticated-orcid":false,"given":"Salmaan","family":"Kanji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9678","key":"10.1016\/j.jcf.2023.01.005_bib0001","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/S0140-6736(09)60327-5","article-title":"Cystic fibrosis","volume":"373","author":"O'Sullivan","year":"2009","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.jcf.2023.01.005_bib0002","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jcf.2023.01.005_bib0003","doi-asserted-by":"crossref","first-page":"928","DOI":"10.3390\/ph14090928","article-title":"State of the art on approved cystic fibrosis transmembrane conductance regulator (CFTR) modulators and triple-combination therapy","volume":"14","author":"Meoli","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.jcf.2023.01.005_bib0004","unstructured":"TRIKAFTA\u00ae (elexacaftor\/tezacaftor\/ivacaftor and ivacaftor)[product monograph]. Toronto, Ontario, Canada: 2023;Vertex Pharmaceuticals (Canada) Inc."},{"key":"10.1016\/j.jcf.2023.01.005_bib0005","unstructured":"European Medicines Agency. Kaftrio [Available from: 2023; https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kaftrio-epar-product-information_en.pdf."},{"issue":"10212","key":"10.1016\/j.jcf.2023.01.005_bib0006","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.jcf.2023.01.005_bib0007","first-page":"2208","article-title":"Triple therapy for cystic fibrosis Phe508del-gating and -residual function genotypes","volume":"385","author":"Barry","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jcf.2023.01.005_bib0008","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A phase 3 open-label study of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508del allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.jcf.2023.01.005_bib0009","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jcf.2013.09.007","article-title":"Sweat chloride as a biomarker of CFTR activity: proof of concept and ivacaftor clinical trial data","volume":"13","author":"Accurso","year":"2014","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.jcf.2023.01.005_bib0010","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jada.2008.02.020","article-title":"Clinical practice guidelines on G, et\u00a0al. evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review","volume":"108","author":"Stallings","year":"2008","journal-title":"J Am Diet Assoc"},{"key":"10.1016\/j.jcf.2023.01.005_bib0011","doi-asserted-by":"crossref","first-page":"l6347","DOI":"10.1136\/bmj.l6347","article-title":"Cystic fibrosis: triple therapy shows promising results","volume":"367","author":"Mahase","year":"2019","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.jcf.2023.01.005_bib0012","first-page":"263","article-title":"Basic review of the cytochrome p450 system","volume":"4","author":"McDonnell","year":"2013","journal-title":"J Adv Pract Oncol"},{"issue":"7","key":"10.1016\/j.jcf.2023.01.005_bib0013","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.2217\/pgs.11.44","article-title":"Transporter-mediated drug-drug interactions","volume":"12","author":"Muller","year":"2011","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jcf.2023.01.005_bib0014","unstructured":"Agency EM. Kaftrio(R) [Available from:2023;https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/kaftrio-epar-public-assessment-report_en.pdf."},{"issue":"1","key":"10.1016\/j.jcf.2023.01.005_bib0015","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1016\/S1569-1993(12)60214-8","article-title":"Drug-drug interactions between ivacaftor and midazolam or rosiglitazone in healthy volunteers","volume":"11","author":"Chen","year":"2012","journal-title":"J Cystic Fibros"},{"issue":"38","key":"10.1016\/j.jcf.2023.01.005_bib0016","first-page":"286","article-title":"The effect of ciprofloxacin, itraconazole, and rifampin on the pharmacokinetics of lumacaftor in combination with ivacaftor in healthy individuals","volume":"49","author":"Pawaskar","year":"2014","journal-title":"Pediatr Pulmonol"},{"issue":"2","key":"10.1016\/j.jcf.2023.01.005_bib0017","first-page":"244","article-title":"Evaluation of the drug-drug interaction potential of rifabutin and elexacaftor\/tezacaftor\/ivacaftor using a physiologically based pharmacokinetic simulation approach","volume":"55","author":"Hong","year":"2020","journal-title":"Pediatr Pulmonol"},{"issue":"3","key":"10.1016\/j.jcf.2023.01.005_bib0018","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1021\/acsptsci.0c00030","article-title":"Metabolomic description of ivacaftor elevating polymyxin B mediated antibacterial activity in cystic fibrosis pseudomonas aeruginosa","volume":"3","author":"Allobawi","year":"2020","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"4","key":"10.1016\/j.jcf.2023.01.005_bib0019","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.93029","article-title":"Chronic beta2AR stimulation limits CFTR activation in human airway epithelia","volume":"3","author":"Brewington","year":"2018","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/j.jcf.2023.01.005_bib0020","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1177\/1945892418815615","article-title":"Ivacaftor, a cystic fibrosis transmembrane conductance regulator potentiator, enhances ciprofloxacin activity against pseudomonas aeruginosa","volume":"33","author":"Cho","year":"2019","journal-title":"Am J Rhinol Allergy"},{"issue":"3","key":"10.1016\/j.jcf.2023.01.005_bib0021","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/cts.12610","article-title":"Pharmacokinetic and drug-drug interaction profiles of the combination of Tezacaftor\/Ivacaftor","volume":"12","author":"Garg","year":"2019","journal-title":"Clin Transl Sci"},{"issue":"5","key":"10.1016\/j.jcf.2023.01.005_bib0022","doi-asserted-by":"crossref","first-page":"E6","DOI":"10.1002\/ppul.23971","article-title":"Sensitivity of ivacaftor to drug-drug interactions with rifampin, a cytochrome P450 3A4 inducer","volume":"53","author":"Guimbellot","year":"2018","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2023.01.005_bib0023","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.pupt.2015.01.003","article-title":"Ivacaftor therapy in siblings with cystic fibrosis-the potential implications of Itraconazole in dosage and efficacy","volume":"31","author":"Harrison","year":"2015","journal-title":"Pulm Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.jcf.2023.01.005_bib0024","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/cpt.2585","article-title":"Physiologically-based pharmacokinetic-led guidance for patients with cystic fibrosis taking elexacaftor-tezacaftor-ivacaftor with nirmatrelvir-ritonavir for the treatment of COVID-19","volume":"111","author":"Hong","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.jcf.2023.01.005_bib0025","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1111\/bcp.13324","article-title":"The pharmacokinetic interaction between ivacaftor and ritonavir in healthy volunteers","volume":"83","author":"Liddy","year":"2017","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.jcf.2023.01.005_bib0026","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jcf.2014.02.004","article-title":"Antibacterial properties of the CFTR potentiator ivacaftor","volume":"13","author":"Reznikov","year":"2014","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2023.01.005_bib0027","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/jcph.377","article-title":"Clinical drug-drug interaction assessment of ivacaftor as a potential inhibitor of cytochrome P450 and P-glycoprotein","volume":"55","author":"Robertson","year":"2015","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.jcf.2023.01.005_sbref0028","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.1016\/j.jcf.2021.04.005","article-title":"Pharmacokinetic interactions between ivacaftor and cytochrome P450 3A4 inhibitors in people with cystic fibrosis and healthy controls","volume":"20","author":"van der Meer","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.01.005_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2019.103355","article-title":"Testing the face validity and inter-rater agreement of a simple approach to drug-drug interaction evidence assessment","volume":"101","author":"Grizzle","year":"2020","journal-title":"J Biomed Inform"},{"issue":"2","key":"10.1016\/j.jcf.2023.01.005_bib0030","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s40264-014-0262-8","article-title":"Consensus recommendations for systematic evaluation of drug-drug interaction evidence for clinical decision support","volume":"38","author":"Scheife","year":"2015","journal-title":"Drug Saf"},{"key":"10.1016\/j.jcf.2023.01.005_bib0031","unstructured":"Contreary C.G., Seay J.E. Trikafta overdose in an adolescent female with cystic fibrosis: a case report 2021 [June 30, 2022]. Available from: https:\/\/www.medschool.lsuhsc.edu\/internal_medicine\/docs\/January_2021_Poster_Session\/Abstracts\/jessica_seay_abstract.pdf."}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323000048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323000048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:47:55Z","timestamp":1761601675000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199323000048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S1569199323000048"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2023.01.005","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-drug interactions with CFTR modulator therapy in cystic fibrosis: Focus on Trikafta\u00ae\/Kaftrio\u00ae","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2023.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}